Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04692688
PHASE2

Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy

Sponsor: Ocuphire Pharma, Inc.

View on ClinicalTrials.gov

Summary

The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).

Official title: Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects With Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy and Mild Proliferative Diabetic Retinopathy

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

103

Start Date

2021-04-08

Completion Date

2023-01-25

Last Updated

2026-06-08

Healthy Volunteers

Yes

Interventions

DRUG

APX3330

APX3330, a small-molecule oral tablet, is a Ref-1 inhibitor that can potentially reduce proinflammatory and hypoxic signaling that contributes to several eye diseases.

DRUG

Placebo

Placebo tablets are identical to APX3330 tablets except for the absence of the active pharmaceutical ingredient.

Locations (24)

Clinical Site 9

Phoenix, Arizona, United States

Clinical Site 8

Bakersfield, California, United States

Clinical Site 5

Beverly Hills, California, United States

Clinical Site 11

Palm Desert, California, United States

Clinical Site 2

Sacramento, California, United States

Clinical Site 24

Walnut Creek, California, United States

Clinical Site 19

Miami, Florida, United States

Clinical Site 7

Winter Haven, Florida, United States

Clinical Site 6

Carmel, Indiana, United States

Clinical Site 14

Hagerstown, Maryland, United States

Clinical Site 22

Springfield, Massachusetts, United States

Clinical Site 17

Grand Blanc, Michigan, United States

Clinical Site 12

Albuquerque, New Mexico, United States

Clinical Site 15

Shirley, New York, United States

Clinical Site 20

Charlotte, North Carolina, United States

Clinical Site 1

Rapid City, South Dakota, United States

Clinical Site 18

Austin, Texas, United States

Clinical Site 16

Bellaire, Texas, United States

Clinical Site 10

Fort Worth, Texas, United States

Clinical Site 4

McAllen, Texas, United States

Clinical Site 3

San Antonio, Texas, United States

Clinical Site 23

San Antonio, Texas, United States

Clinical Site 13

Southlake, Texas, United States

Clinical Site 21

Ogden, Utah, United States